From GlobeNewswire: 2025-06-17 16:05:00

Madrigal Pharmaceuticals granted equity awards to 36 new non-executive employees under its 2023 Inducement Plan. The awards consist of options to purchase 2,184 shares of common stock and 21,125 restricted stock units. Options vest quarterly starting on the first anniversary, while restricted stock units vest in four equal installments. The awards are contingent on continued employment. Madrigal is focused on developing therapeutics for metabolic dysfunction-associated steatohepatitis. Its medication, Rezdiffra, is the first FDA-approved treatment for MASH with moderate to advanced fibrosis. A Phase 3 trial is ongoing for MASH cirrhosis. Visit www.madrigalpharma.com for more information.



Read more at GlobeNewswire: Madrigal Pharmaceuticals Announces Grants of Inducement